News Has mRNA delivered a breakthrough in quest for HIV cure? A new way to deliver mRNA to T cells could allow HIV that is hiding away to be exposed and targeted with antiretroviral therapies, say scientists.
News UK's HIV response is 'failing women' Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.
Patients Gilead's HIV success and controversy: Expanding access amid ... Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.
News Gilead, MSD say HIV combo could be weekly, oral HIV drug In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients
News Gilead strikes deal to expand HIV drug access in 120 countri... Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face